Ewha Med J.  2023 Dec;46(S1):e24. 10.12771/emj.2023.e24.

Inflammatory Response Markers as Predictors of Colorectal Cancer Prognosis

• Kim M
• Son IT
• Oh BY

• KMID: 2550844
• DOI: http://doi.org/10.12771/emj.2023.e24

Abstract

Colorectal cancer (CRC) is a globally prevalent and challenging malignancy. Accurate prognosis prediction is essential for optimizing patient care. This comprehensive review discusses the intricate relationships between inflammatory response markers and CRC prognosis. Inflammatory response markers have gained prominence as a prognostic tool. Elevations in the preoperative neutrophillymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein-albumin ratio predict a poor prognosis for patients with CRC. A decreased lymphocyte-monocyte ratio is also a poor prognostic factor. A high Glasgow prognostic score and a high modified Glasgow prognostic score are associated with adverse outcomes, including reduced survival. While significant progress has been made, challenges remain in standardizing the clinical application of these inflammatory response markers. Prospective research and further investigations are warranted to refine the prognostic models. Enhanced understanding and utilization of these inflammatory response markers will help advance personalized treatment strategies, refine surveillance protocols, and improve the management of CRC.

Keyword

Colorectal neoplasms; Inflammatory response marker; Prognosis

Reference

References

1. Kim MH, Park S, Yi N, Kang B, Park IJ. Colorectal cancer mortality trends in the era of cancer survivorship in Korea: 2000–2020. Ann Coloproctol. 2022; 38(5):343–352. DOI: 10.3393/ac.2022.00535.0076. PMID: 36353833. PMCID: PMC9650346.

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71(1):7–33. DOI: 10.3322/caac.21654. PMID: 33433946.

3. An S, Shim H, Kim K, Kim B, Bang HJ, Do H, et al. Pretreatment inflammatory markers predicting treatment outcomes in colorectal cancer. Ann Coloproctol. 2022; 38(2):97–108. DOI: 10.3393/ac.2021.01004.0143. PMID: 35345306. PMCID: PMC9021854.

4. Kim JC, Bodmer WF. Genotypic and phenotypic characteristics of hereditary colorectal cancer. Ann Coloproctol. 2021; 37(6):368–381. DOI: 10.3393/ac.2021.00878.0125. PMID: 34961301. PMCID: PMC8717071.

5. Lim Y, Gang DY, Lee WY, Yun SH, Cho YB, Huh JW, et al. Proteomic identification of arginine-methylated proteins in colon cancer cells and comparison of messenger RNA expression between colorectal cancer and adjacent normal tissues. Ann Coloproctol. 2022; 38(1):60–68. DOI: 10.3393/ac.2020.00899.0128. PMID: 35081685. PMCID: PMC8898628.

6. Kim YH, Kim KJ. Upregulation of prostaglandin E2 by inducible microsomal prostaglandin E synthase-1 in colon cancer. Ann Coloproctol. 2022; 38(2):153–159. DOI: 10.3393/ac.2021.00374.0053. PMID: 34465013. PMCID: PMC9021850.

7. Park IJ. Precision medicine for primary rectal cancer will become a reality. Ann Coloproctol. 2022; 38(4):281–282. DOI: 10.3393/ac.2022.00500.0071. PMID: 36059074. PMCID: PMC9441542.

8. Eom T, Lee Y, Kim J, Park I, Gwak G, Cho H, et al. Prognostic factors affecting disease-free survival and overall survival in T4 colon cancer. Ann Coloproctol. 2021; 37(4):259–265. DOI: 10.3393/ac.2020.00759.0108. PMID: 34167188. PMCID: PMC8391044.

9. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová , Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014; 134(11):2513–2522. DOI: 10.1002/ijc.28384. PMID: 23852704. PMCID: PMC4217376.

10. Lech G, Słotwiński R, Słodkowski M Jr, Krasnodębski IW. Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World J Gastroenterol. 2016; 22(5):1745–1755. DOI: 10.3748/wjg.v22.i5.1745. PMID: 26855534. PMCID: PMC4724606.

11. Joo JI, Lim SW, Oh BY. Prognostic impact of carcinoembryonic antigen levels in rectal cancer patients who had received neoadjuvant chemoradiotherapy. Ann Coloproctol. 2021; 37(3):179–185. DOI: 10.3393/ac.2020.11.27. PMID: 33971705. PMCID: PMC8273711.

12. Kang S. Carcinoembryonic antigen, the most accessible test for predicting colorectal cancer prognosis: exploring alternative roles. Ann Coloproctol. 2021; 37(3):129–130. DOI: 10.3393/ac.2021.00493.0070. PMID: 34233114. PMCID: PMC8273716.

13. Guo J, Chok AY, Lim HJ, Tay WX, Lye WK, Samarakoon LB, et al. Prognostic value of neutrophil-to-lymphocyte ratio in obstructing colorectal cancer treated by endoscopic stenting as a bridge to surgery. Ann Coloproctol. 2021; 37(3):159–165. DOI: 10.3393/ac.2020.05.25. PMID: 34044498. PMCID: PMC8273718.

14. An SH, Kim IY. Can pretreatment platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict long-term oncologic outcomes after preoperative chemoradiation followed by surgery for locally advanced rectal cancer? Ann Coloproctol. 2022; 38(3):253–261. DOI: 10.3393/ac.2021.00633.0090. PMID: 35249276. PMCID: PMC9263313.

15. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436–444. DOI: 10.1038/nature07205. PMID: 18650914.

16. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860–867. DOI: 10.1038/nature01322. PMID: 12490959. PMCID: PMC2803035.

17. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6):883–899. DOI: 10.1016/j.cell.2010.01.025. PMID: 20303878. PMCID: PMC2866629.

18. Chiang SF, Hung HY, Tang R, Changchien CR, Chen JS, You YT, et al. Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis. 2012; 27:1347–1357. DOI: 10.1007/s00384-012-1459-x. PMID: 22460305.

19. Guthrie GJK, Roxburgh CSD, Farhan-Alanie OM, Horgan PG, McMillan DC. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2013; 109(1):24–28. DOI: 10.1038/bjc.2013.330. PMID: 23799846. PMCID: PMC3708558.

20. Malietzis G, Giacometti M, Askari A, Nachiappan S, Kennedy RH, Faiz O, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014; 260(2):287–292. DOI: 10.1097/SLA.0000000000000216. PMID: 24096764.

21. Li Y, Jia H, Yu W, Xu Y, Li X, Li Q, et al. Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection. Int J Cancer. 2016; 139(1):220–231. DOI: 10.1002/ijc.30071. PMID: 26933932.

22. Inamoto S, Kawada K, Okamura R, Hida K, Sakai Y. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2019; 34(7):1303–1315. DOI: 10.1007/s00384-019-03316-z. PMID: 31177316.

23. Song Y, Yang Y, Gao P, Chen X, Yu D, Xu Y, et al. The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer. BMC Cancer. 2017; 17(1):744. DOI: 10.1186/s12885-017-3752-0. PMID: 29126400. PMCID: PMC5681757.

24. Pedrazzani C, Mantovani G, Fernandes E, Bagante F, Salvagno GL, Surci N, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep. 2017; 7(1):1494. DOI: 10.1038/s41598-017-01652-0. PMID: 28473700. PMCID: PMC5431463.

25. Nagasaki T, Akiyoshi T, Fujimoto Y, Konishi T, Nagayama S, Fukunaga Y, et al. Prognostic impact of neutrophil-to-lymphocyte ratio in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy. Dig Surg. 2015; 32(6):496–503. DOI: 10.1159/000441396. PMID: 26544755.

26. Zhang Y, Liu X, Xu M, Chen K, Li S, Guan G. Prognostic value of pretreatment systemic inflammatory markers in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Sci Rep. 2020; 10(1):8017. DOI: 10.1038/s41598-020-64684-z. PMID: 32415197. PMCID: PMC7228917.

27. Yoshida D, Minami K, Sugiyama M, Ota M, Ikebe M, Morita M, et al. Prognostic impact of the neutrophil-to-lymphocyte ratio in stage I-II rectal cancer patients. J Surg Res. 2020; 245:281–287. DOI: 10.1016/j.jss.2019.07.072. PMID: 31421374.

28. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 2010; 25(12):1427–1433. DOI: 10.1007/s00384-010-1052-0. PMID: 20821217.

29. Hung HY, Chen JS, Yeh CY, Changchien CR, Tang R, Hsieh PS, et al. Effect of preoperative neutrophil–lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis. 2011; 26(8):1059–1065. DOI: 10.1007/s00384-011-1192-x. PMID: 21479566.

30. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008; 34(1):55–60. DOI: 10.1016/j.ejso.2007.02.014. PMID: 17448623.

31. Mao R, Zhao JJ, Bi XY, Zhang YF, Li ZY, Huang Z, et al. A low neutrophil to lymphocyte ratio before preoperative chemotherapy predicts good outcomes after the resection of colorectal liver metastases. J Gastrointest Surg. 2019; 23(3):563–570. DOI: 10.1007/s11605-018-3796-8. PMID: 30066069.

32. Erstad DJ, Taylor MS, Qadan M, Tanabe KK, Chang DC, Ferrone CR, et al. Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. Am J Surg. 2020; 220(6):1579–1585. DOI: 10.1016/j.amjsurg.2020.05.003. PMID: 32580870.

33. Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, et al. Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: colon inflammatory index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. Cancer Manag Res. 2019; 11:4357–4369. DOI: 10.2147/CMAR.S198651. PMID: 31191000. PMCID: PMC6522652.

34. Ozawa T, Ishihara S, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, et al. The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer. Int J Colorectal Dis. 2015; 30(9):1165–1171. DOI: 10.1007/s00384-015-2276-9. PMID: 26049902.

35. Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg. 2017; 265(3):539–546. DOI: 10.1097/SLA.0000000000001743. PMID: 27070934. PMCID: PMC5300029.

36. Dolan RD, McSorley ST, Park JH, Watt DG, Roxburgh CS, Horgan PG, et al. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018; 119(1):40–51. DOI: 10.1038/s41416-018-0095-9. PMID: 29789606. PMCID: PMC6035216.

37. Chen XQ, Xue CR, Hou P, Lin BQ, Zhang JR. Lymphocyte-to-monocyte ratio effectively predicts survival outcome of patients with obstructive colorectal cancer. World J Gastroenterol. 2019; 25(33):4970–4984. DOI: 10.3748/wjg.v25.i33.4970. PMID: 31543687. PMCID: PMC6737316.

38. Lu X, Guo W, Xu W, Zhang X, Shi Z, Zheng L, et al. Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients. Cancer Manag Res. 2019; 11:229–249. DOI: 10.2147/CMAR.S185350. PMID: 30636896. PMCID: PMC6307678.

39. Choi KW, Hong SW, Chang YG, Lee WY, Lee B, Paik IW, et al. Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients. Ann Surg Treat Res. 2014; 86(6):309–313. DOI: 10.4174/astr.2014.86.6.309. PMID: 24949322. PMCID: PMC4062449.

40. Lee SC, Huh JW, Lee WY, Yun SH, Kim HC, Cho YB, et al. Prognostic value of serum inflammatory markers in colorectal cancer. Int J Colorectal Dis. 2020; 35(7):1211–1219. DOI: 10.1007/s00384-020-03591-1. PMID: 32306074.

41. Roxburgh CS, Salmond JM, Horgan PG, Oien K, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009; 249(5):788–793. DOI: 10.1097/SLA.0b013e3181a3e738. PMID: 19387324.

42. Tokunaga R, Sakamoto Y, Nakagawa S, Izumi D, Kosumi K, Taki K, et al. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection. Int J Clin Oncol. 2017; 22(4):740–748. DOI: 10.1007/s10147-017-1102-5. PMID: 28213742.

43. Leitch EF, Chakrabarti M, Crozier JEM, McKee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007; 97(9):1266–1270. DOI: 10.1038/sj.bjc.6604027. PMID: 17923866. PMCID: PMC2360467.

44. Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 2016; 263(2):326–336. DOI: 10.1097/SLA.0000000000001122. PMID: 25575264.

45. Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kondo T, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018; 267(3):527–531. DOI: 10.1097/SLA.0000000000002115. PMID: 27984214.